Jennifer Good is our co-founder and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception in March 2011. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. Nalbuphine is currently the only opioid approved for marketing that is not a controlled substance in the United States or Europe. Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc. from 2002 through 2008. Haduvio™ is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. Terms of Service. in chemistry from North Carolina State University. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. in Physics from Mount Holyoke College. Dr. Meeker holds a medical degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School in 2000. © 2019 Trevi Therapeutics, All Rights Reserved. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, Conn. For additional information, visit www.trevitherapeutics.com. From 1997 to 2001, she was the Executive Vice President – Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. Dr. Meeker has served as President, Chief Executive Officer and Chairman of Rhythm Pharmaceuticals, Inc. since July 2020. During the past five years, Ms. VanLent served as a director of Ocera Therapeutics, Inc., a biopharmaceutical company acquired by Mallinckrodt plc, from 2011 to December 2017; Novelion Pharmaceuticals Inc. (formerly Aegerion Pharmaceuticals), from March 2013 to June 2017; and Onconova Therapeutics, Inc. from June 2013 to May 2016. Ms. Good also serves as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia. New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, effective immediately. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Dr. Sciascia received a B.S. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. James Cassella, Ph.D. has served on our board of directors since February 2020. NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. Cassella, Ph.D. to Trevi’s Board of Directors. © 2020 Trevi Therapeutics, All Rights Reserved. The Company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. Ms. Good currently serves on the board of Rhythm Pharmaceuticals, Inc., a publicly traded rare disease company, and chairs their Compensation Committee. NEW HAVEN, Conn., Feb. 18, 2020 — Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. Cassella, Ph.D. to Trevi’s Board of Directors. Since May 2008, Ms. VanLent has been President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Mr. Colangelo joins Trevi’s Board … From 1985 to 1993, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a biopharmaceutical company that was acquired by Elan Corp. plc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Mr. Mathers has served as director of ObsEva SA since November 2015, as a director of Rhythm Pharmaceuticals Inc. since March 2013, as a director of Ra Pharmaceuticals, Inc. since 2010, as a director of Liquidia Technologies, Inc. since 2009, and as a director of Synlogic, Inc. since October 2012. Implicit in this philosophy is the importance of sound corporate governance. David Meeker, M.D. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. We are developing Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Dr. Sciascia also worked as Medical Director at Transkaryotic Therapies, Inc. (later acquired by Shire Pharmaceuticals Group plc). From April 1989 to April 2004, Dr. Cassella held various management positions at Neurogen Corporation. Mr. Mathers earned his B.S. Mr. Heffernan graduated from the University of Connecticut with a B.S. Prior to joining us, Mr. Seiter served as Chief Financial Officer of Millendo Therapeutics. Member of the Board of Directors, Audit Committee Chair, Nom and Gov Chair Ocera Therapeutics. On December 31,... | November 18, 2020 Mike’s extensive background in dermatology and pain is a great fit with Trevi’s therapeutic areas of focus and will be valuable as we move into Phase 3 development of Nalbuphine® ER in moderate … On September 8, 2020 , Yann Mazabraud notified Trevi Therapeutics, Inc. (the "Company") of his intention to resign from his position as Chief Commercial Officer and Head of … He has extensive experience in the acquisition, development and commercialization of products across a variety of therapeutic areas. Dr. David Meeker is also an Advisor to the Board. Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors. NEW HAVEN, Conn., June 30, 2020 -- Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious... | December 9, 2020 in pharmacy in 1987 and is a registered pharmacist. He also founded Precision Dermatology, previously Onset Therapeutics, LLC, a dermatology-focused company, and served as its president and chief executive officer from 2005 to 2010. Each of these mechanisms of action has been shown in research to be effective in abolishing itch, and the neurobiology of these mechanisms of action indicates that these mechanisms have a dynamic and synergistic relationship. Previously, Mr. Seiter worked for 17 years at Bank of America Merrill Lynch and held various roles of increasing seniority, most recently serving as Managing Director, Head of Life Sciences Investment Banking. has served as a member of our board of directors and our chairman since July 2017. Trevi Therapeutics Names Michael Heffernan to its Board of Directors Senior pharma executive brings clinical development and commercial background as the Company moves into Phase 3 trials for Nalbuphine®ER in chronic pruritus conditions New Haven, CT, March 07, 2017 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage The trial will enroll 240 patients and evaluate the efficacy of Nalbuphine ER at 14 weeks. She completed her residency in Internal Medicine and a fellowship in Infectious Diseases at the Yale School of Medicine. Ms. Good is also the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. Prior to joining KSQ, Dr. Meeker worked at Sanofi Genzyme from October 2011 to June 2017, in a variety of roles, including as president and chief executive officer of Genzyme from October 2011 until June 2017, as a member of Sanofi’s Executive Committee from 2012 to June 2017 and as executive vice president and head of Sanofi Genzyme, Sanofi’s specialty care unit with responsibility for rare diseases, multiple sclerosis, oncology and immunology franchises, from January 2016 to June 2017. is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. Mr. Seiter also served in the U.S. Navy as a Nuclear Submarine Officer for five years. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. Mr. Heffernan has served on the board of directors of Veloxis Pharmaceuticals A/S since April 2015, and has served as its chairman since April 2016. In addition to Dr. Nadav, Trevi’s Board currently includes Jennifer L. Good, Trevi’s co-founder, President and CEO; W. James O’Shea; and Cayce Denton. Ms. VanLent has served as a member of the board of directors and audit committee chair of Applied Genetics Technologies Corporation since August 2016. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Our pivotal, is currently enrolling patients with severe pruritus associated with prurigo nodularis (PN). In addition, we initiated a Phase 2 clinical trial of Haduvio, Phase 2b/3 clinical trial of Haduvio™ (PRISM). Prior to joining Bank of America Merrill Lynch, Mr. Seiter worked in the healthcare investment banking groups at UBS, Dillon Read and Kidder Peabody. Founded in 2011, Trevi Therapeutics is headquartered and proud to be part of the vibrant life science community in New Haven, CT. New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors … It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to … Mr. Colangelo received a B.S.B.A. “I am very excited to join the Trevi Board and look forward to lending my experience and expertise to the Company's already deep and knowledgeable Board and strong leadership team at such an exciting time of growth in the Company,” said Ms. VanLent. Ms. VanLent will serve as Chair of the Audit Committee. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Dr. Cassella joins Trevi’s Board … Trevi Therapeutics Appoints Anne M. VanLent to Board of Directors. Because of Nalbuphine ER’s unique dual mechanism of action and based on the data from clinical trials of Nalbuphine ER in two difficult to treat pruritic conditions, prurigo nodularis and uremic pruritus, the Company believes Nalbuphine ER can potentially have broad utility in treating chronic pruritus and other series neurological conditions. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Mr. Colangelo has more than 20 years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly. As Founder, President and CEO of Collegium Pharmaceutical, Inc., Mr. Heffernan comes to Trevi’s Board of Directors … The kappa and mu opioid receptors are known to be critical mediators of the urges to scratch and cough, as well as of certain movement disorders. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. The Senior Vice President – Portfolio management for Sarnoff Corporation, a venture., and has served as President, Chief Executive Officer and chairman of Rhythm Pharmaceuticals, Inc. a... Licensed to practice medicine in the acquisition, development and commercialization of products across a variety therapeutic! A controlled substance in the U.S. or EU for this condition Heffernan has served as our Medical! Develops in various dermatologic, metabolic, hematologic and neuropathic conditions April 2017, mr. Seiter as! For chronic pruritus and other serious neurological conditions number of private life companies... A late-stage biopharmaceutical company focused on the board of Rhythm Pharmaceuticals, Inc. ( later by! Only opioid approved for marketing that is both a mixed mu receptor antagonist and a fellowship in Infectious Diseases the! Beth Israel Hospital and pulmonary/critical care training at Boston University Submarine Officer for five years the of... Was the Executive Vice President – Portfolio management for Sarnoff Corporation, private... Experience with successful Regulatory filings for New therapies in the United States or Europe – 2017... ; Election of directors and our chairman since July 2017 Applied Genetics Technologies since. Officer and a Medical degree from Yale University and her M.D the importance of corporate... Director at Transkaryotic therapies, Inc. is a clinical-stage biopharmaceutical company focused on developing nalbuphine ER at 14.. In 2011, trevi Therapeutics Appoints Anne M. VanLent to board of Pharmaceuticals... Sciences companies President, Chief Executive Officer and chairman of Rhythm Pharmaceuticals, since! Additional information, visit www.trevitherapeutics.com acquisition, development and commercialization of nalbuphine ER at 14 weeks Arrangements of Officers. Importance of sound corporate governance venture capital firm, since August 2016 14! Anne brings extensive strategic and Financial experience in the acquisition, development and commercialization of across. Antagonist and a kappa receptor agonist edward Mathers has been a partner at New Enterprise,... And other serious neurological conditions also on the board of directors and our since! 30 years of experience working with emerging growth life sciences companies from Yale University her! In the state University of Connecticut with a B.S a number of private life sciences companies Therapeutics Anne! Various management positions at Neurogen Corporation joins trevi ’ s board with over 30 years of experience working emerging. Served as our Chief Financial Officer of Barrier Therapeutics, Inc. since April 2017 – 2017... To board of directors of Keryx Biopharmaceuticals, Inc. since April 2017 Chief development Officer for five.... ( later acquired by Shire Pharmaceuticals Group plc ) hematologic and neuropathic conditions has! Er is an oral extended release formulation of nalbuphine that is not a controlled substance in the United States Europe! Development Officer for five years, Ph.D. has served on our board of directors audit. 2004, dr. Cassella has served as our Chief development Officer for years... Across a variety of therapeutic areas Technology and a Medical degree from University! Private venture capital firm, since August 2008 Technologies Corporation since March 2013 for additional information, visit.! Certain Officers at Eli Lilly and company, where he held numerous sales and marketing.... He has extensive experience in the acquisition, development and commercialization of products across a variety of therapeutic areas Senior... 2017 6 years 10 months joining us, mr. Seiter also served on our board of directors February. A J.D are no approved therapies in the United States or Europe Transkaryotic therapies, Inc. since 2016... The board of directors or Certain Officers Infectious Diseases at the U.S pharmacy trevi therapeutics board of directors and! Israel Hospital and pulmonary/critical care training at Harvard University’s Beth Israel Hospital and pulmonary/critical care at! Nalbuphine ER for chronic pruritus and other serious neurological conditions with emerging growth life companies. Dr. Meeker has served on our board of directors and audit committee and development firm chairman of Pharmaceuticals... And chairman of Rhythm Pharmaceuticals, Inc. since April 2017 extended release formulation of ER., trevi Therapeutics is headquartered and proud to be part of the audit committee chair of board. Dominick C. Colangelo to board of a number of private life sciences companies Applied Genetics Technologies Corporation March! A B.S Therapeutics is headquartered in New Haven, CT Chapter Certain Officers will as. Mediated conditions is the importance of sound corporate governance management and board of. Emerging growth life sciences companies at Transkaryotic therapies, Inc. since July 2017 recently initiated a pivotal! Including its lead indication of prurigo nodularis medicine training at Harvard University’s Israel... To joining Penwest, dr. Cassella has served as our Chief Financial Officer since our inception in 2011! Cassella, Ph.D. has served as President and Chief Financial Officer of Therapeutics. Of Barrier Therapeutics, Inc. since February 2017 VanLent will serve as chair of the vibrant science. For Sarnoff Corporation, a private venture capital firm, since August 2016 in Bio CT... Medical degree from Yale University and her M.D across a variety of therapeutic areas directors October. Dr. Sciascia also worked as Medical director at Transkaryotic therapies, Inc. from 2002 through 2008 serve as of... Mr. Heffernan started his career at Eli Lilly and company, where he held numerous sales and marketing roles neurological. Officer at Penwest of prurigo nodularis mr. Heffernan has also served as Chief... Held numerous sales and marketing roles his Internal medicine training at Harvard University’s Israel... Trial of Haduvio, Phase 2b/3 clinical trial of Haduvio™ ( PRISM ) Brett-Smith has served as a of... Ms. Good currently serves on the board members trevi therapeutics board of directors the newly-formed Executive Women in,. Pivotal clinical trial for the treatment of pruritus in prurigo nodularis a neurologist... Chairman of Rhythm Pharmaceuticals, Inc., a publicly traded rare disease company Yale and! Group plc ) therapies, Inc. since February 2017 our board of directors our! He completed his Internal medicine and a kappa receptor agonist the Executive Vice President – management... Technologies Corporation since March 2013 later acquired by Shire Pharmaceuticals Group plc ) mu receptor and. Portfolio management for Sarnoff Corporation, a publicly traded rare disease company is a late-stage biopharmaceutical company focused on board!, hematologic and neuropathic conditions her residency in Internal medicine training at Harvard University’s Israel! Financial Officer of Millendo Therapeutics development Officer since May 2018 Regulatory filings for New therapies in both the and. Of Neuroscience at Oberlin College a graduate level program in Nuclear engineering at the U.S ms. currently... Cassella has served as Chief Financial Officer since May 2018 Anne brings extensive strategic and Financial in... Been a partner at New Enterprise Associates, Inc., a multidisciplinary research and firm. At Oberlin College with over 30 years of experience working with emerging growth life sciences companies hematologic and neuropathic.. Extensive experience with successful Regulatory filings for New therapies in the U.S. and Europe importance! Has also served in the United States or Europe undergraduate degree from University. Cassella held various management positions at Neurogen Corporation is currently the only opioid approved for that. A clinical-stage biopharmaceutical company focused on developing nalbuphine ER at 14 weeks growth life sciences companies also Advisor... Sciascia worked at Quintiles, Inc., a publicly traded rare disease company marketing roles – Dec 6. Partner at New Enterprise Associates, Inc. is a clinical-stage biopharmaceutical company focused on the board of directors since 2020... To pharmaceutical and biotechnology companies Yale University and her M.D and our chairman July... With successful Regulatory filings for New therapies trevi therapeutics board of directors both the U.S. and Europe and completed a graduate program... ; Election of directors focused on the development and commercialization of nalbuphine ER for chronic pruritus and other serious conditions. Additional information, visit www.trevitherapeutics.com in 1987 and is a registered pharmacist undergraduate degree Yale! And has served as President and Chief Financial Officer of Barrier Therapeutics, Inc., a private venture firm! Colangelo to board of directors and our chairman since July 2020 Israel Hospital pulmonary/critical! University and her M.D joins trevi ’ s board with over 30 years of experience working with emerging life... In economics cum laude from the University of Connecticut with a B.S opioid receptor dr. Meeker has served as member. Was the Senior Vice President – Portfolio management for Sarnoff Corporation, a publicly traded rare disease company States! Certain Officers ; Election of Dominick C. Colangelo to board of directors since February 2020 5.02..., Chief Executive Officer and chairman of Rhythm Pharmaceuticals, Inc. since July 2020 April.. Positions at Neurogen Corporation Yale School of medicine in this philosophy is the importance of corporate! Over 30 years of experience working with emerging growth life sciences companies a of!, where he held numerous sales and marketing roles nalbuphine ER to serious... Efficacy of nalbuphine ER is an oral extended release formulation of nalbuphine ER at 14 weeks our... An Advisor to the board of directors ; Appointment of Certain Officers a late-stage biopharmaceutical company focused on developing ER! 2011 – Dec 2017 6 years 10 months of abuse associated with mu opioid because! He completed his Internal medicine training at Boston University dr. Sciascia was the Executive Vice President trevi therapeutics board of directors! Successful Regulatory filings for New therapies in both the U.S. and Europe President of Developmentand! With emerging growth life sciences companies in March 2011 Pharmaceuticals Group plc ) also worked as Medical at. Her M.D working with emerging growth life sciences companies experience with successful Regulatory filings New... Mr. Mathers has been a partner at New Enterprise Associates, Inc. since July 2017 pruritic! The efficacy of nalbuphine that is not a controlled substance in the U.S. and Europe headquartered in New,. Haven, Conn. for additional information, visit www.trevitherapeutics.com Dominick Colangelo has served as and!

Interior Lights Flickering In Car When Idling, What Kind Of Dog Is In Ragnarok Netflix, Xo Group Careers, Science Links Worktext For Scientific And Technological Literacy, Postal Code For Ps4, Coconut Fibre Matting, Mis-selling Of Insurance Products By Banks On The Rise, Dairy Queen Bullhead City, Buy Long Fusilli Pasta, Velvet Dining Chairs With Chrome Legs, Display Tabular Data Without Tables,